On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister
April 3, 2020
- PMDA Introduces 3 New Consultation Services
April 2, 2020
- PMDA Issues Q&A for Trial Implementations in Coronavirus Crisis
April 2, 2020
- Keidanren Calls for Review of Health Coverage for OTC-Like Drugs
April 2, 2020
- Japan’s Healthcare Would Collapse before “Overshoot,” Govt Panel Warns
April 2, 2020
- Japan Ruling Parties Call for Fund to Support Healthcare Delivery System
April 2, 2020
- MHLW Orders Label Revisions for Keytruda, Xofluza and More; 1st MID-NET-Based Safety Step Taken
April 1, 2020
- LDP to Suspend Committee Meetings from April 2-12
April 1, 2020
- Govt, LDP Moving to Review Supply Chains in Response to COVID-19 Pandemic
April 1, 2020
- Japan’s 1st In Vitro Diagnostic Test Kit for Novel Coronavirus Approved: Sysmex
March 31, 2020
- Global Health Confab Issues Proposals for Regulatory Harmonization in Asia
March 31, 2020
- Japan Hammers Out New 5-Year Health, Medical Strategy
March 30, 2020
- New Stable Supply Panel Wants to Define “Key Drugs” by This Summer
March 30, 2020
- PMDA Asking Companies to Seek Advice for Trial Rescheduling
March 30, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Ex-Tokyo Tech President Yoshinao Mishima Named AMED Chief from April
March 30, 2020
- Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate
March 27, 2020
- ICH Vancouver Meeting Cancelled due to COVID-19 Pandemic
March 27, 2020
- MHLW to Make Pediatric Medical Database Available to Researchers on Trial Basis
March 26, 2020
- OxyContin’s Chronic Pain Nod Delayed as Distribution System Not Ready
March 26, 2020
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…